A multicenter phase II study of adjuvant chemotherapy with oral fluoropyrimidine s-1 for non-small-cell lung cancer: High completion and survival rates

Clinical Lung Cancer

Volumn 13, Issue 6, 2012, Pages 464-469

  Tsuchiya, Tomoshi ^a   Nagayasu, Takeshi ^a   Yamasaki, Naoya ^a   Matsumoto, Keitaro ^a   Miyazaki, Takuro ^a   Tagawa, Tsutomu ^b   Nakamura, Akihiro ^c   Minami, Hiroyuki ^c   Taniguchi, Hideki ^d   Akamine, Shinji ^e   Hisano, Hiroshi ^f   Taniguchi, Yoshitaka ^g  

^a NAGASAKI UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c Department of Surgery   (Japan)

^d JAPANESE RED CROSS NAGASAKI GENBAKU HOSPITAL   (Japan)

^e OITA PREFECTURAL HOSPITAL   (Japan)

^f Nagasakiken Saiseikai Hospital   (Japan)

^g Fukuda Geka Hospital   (Japan)

Author keywords

5 fluorouracil; Adjuvant chemotherapy; Feasibility study

Indexed keywords

ALANINE AMINOTRANSFERASE; AMYLASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMYLASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FEVER; HUMAN; HYPOKALEMIA; INCIDENCE; LACRIMATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALAISE; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OUTPATIENT CARE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PILOT STUDY; POSTOPERATIVE PERIOD; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; SIDE EFFECT; STOMATITIS; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; AMBULATORY CARE; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; TEGAFUR; TREATMENT OUTCOME;

EID: 84867562693     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2012.01.005     Document Type: Article

References (17)

1. H. Kato, Y. Ichinose, M. Ohta A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung N Engl J Med 350 2004 1713 1721
2. R. Arriagada, B. Bergman, A. Dunant Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer N Engl J Med 350 2004 351 360
3. T. Winton, R. Livingston, D. Johnson Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer N Engl J Med 352 2005 2589 2597
4. T. Shirasaka, Y. Shimamato, H. Ohshimo Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators Anticancer Drugs 7 1996 548 557
5. N.J. Vogelzang Continuous infusion chemotherapy: a critical review J Clin Oncol 2 1984 1289 1304
6. T. Shirasaka, Y. Shimamoto, M. Fukushima Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats Cancer Res 53 1993 4004 4009
7. K. Kubota The four-arm cooperative study (FACS) for advanced non-small-cell lung cancer (NSCLC) Proc Am Soc Clin Oncol 22 2004 254 (abstract)
8. M. Kawahara, K. Furuse, Y. Segawa Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer Br J Cancer 85 2001 939 943
9. K. Ota, T. Taguchi, K. Kimura Report on nationwide pooled data and cohort investigation in UFT phase II study Cancer Chemother Pharmacol 22 1988 333 338
10. Y. Basaki, L. Chikahisa, K. Aoyagi Gamma-hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor Angiogenesis 4 2001 163 173
11. T. Kinoshita, A. Nashimoto, Y. Yamamura Feasibility study of adjuvant chemotherapy with S-1 (TS-1; tegafur, gimeracil, oteracil potassium) for gastric cancer Gastric Cancer 7 2004 104 109
12. S. Sakuramoto, M. Sasako, T. Yamaguchi Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine N Engl J Med 357 2007 1810 1820
13. T. Yano, K. Yamazaki, R. Maruyama Feasibility study of postoperative adjuvant chemotherapy with S-1 (tegaful, gimeracil, oteracil potassium) for non-small-cell lung cancer-LOGIK 0601 study Lung Cancer 67 2010 184 187
14. P.M. Calabro-Jones, J.E. Byfield, J.F. Ward Time-dose relationships for 5-fluorouracil cytotoxicity against human epithelial cancer cells in vitro Cancer Res 42 1982 4413 4420
15. F. Tanaka, H. Wada, M. Fukushima UFT and S-1 for treatment of primary lung cancer Gen Thorac Cardiovasc Surg 58 2010 3 13
16. I. Okamoto, H. Yoshioka, S. Morita Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study J Clin Oncol 28 2010 5240 5246
17. M. Takeda, I. Okamoto, N. Hirabayashi Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer Lung Cancer 73 2011 103 109